Core Points - AbbVie has announced the appointment of Robert A. Michael as the new CEO, succeeding Richard A. Gonzalez, who will now serve as executive chairman [1][2] - Robert A. Michael has extensive experience in various leadership roles within AbbVie, including president and chief operating officer, and has been part of the Executive Leadership Team for many years [2][3] - The transition in leadership is aimed at continuing AbbVie's mission to deliver innovative medicines and to drive the next phase of growth for the company [3][4] Company Overview - AbbVie's mission focuses on discovering and delivering innovative medicines that address serious health issues and future medical challenges across key therapeutic areas such as immunology, oncology, neuroscience, and eye care [4]

These stocks could be ideal for investors in their golden years.Most retirees prefer low turnover in their investment portfolios. The less drama, the better. That way, they can focus on doing what they enjoy instead of worrying about their investments.Three Motley Fool contributors think they've found magnificent stocks retirees can buy and hold forever. Here's why they picked AbbVie (ABBV 1.50%), Gilead Sciences (GILD -0.32%), and Johnson & Johnson (JNJ 0.25%).A Dividend King poised for growthKeith Speight ...

AbbVie (ABBV) announced that it has acquired Celsius Therapeutics, a private biotech making novel therapies for treating inflammatory bowel diseases (“IBD”).The acquisition will add Celsius Therapeutics’ lead pipeline candidate, CEL383, to AbbVie’s pipeline. CEL383 is a potential first-in-class TREM1 inhibitor, which has completed phase I study in IBD conditions. AbbVie will pursue further development of CEL383.TREM1 has been identified as a key gene involved in inflammation pathways associated with IBD. In ...

If approved, epcoritamab (TEPKINLY®) will become the first and only bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of prior therapyPositive CHMP opinion based on results from the Phase 1/2 EPCORE® NHL-1 studyNORTH CHICAGO, Ill., June 28, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) ...

AbbVie (ABBV) announced that the FDA approved its lymphoma drug Epkinly (epcoritamab) for a second indication — follicular lymphoma (FL). The drug has been developed in partnership with Genmab (GMAB) .The FDA approved Epkinlyunder the accelerated pathway to treat adults with relapsed or refractory (R/R) FL after two or more lines of therapies. The agency initially granted accelerated approval to the drug last year to treat patients with R/R diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphom ...

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this drugmaker have returned +10.6% over the past month versus the Zacks S&P 500 composite's +3.4% change. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has gained 5.2% over this period. Now the key question is: Where could the stock be headed in the near term?Although ...

Celsius' CEL383 is a potential first-in-class anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody for the treatment of inflammatory bowel disease (IBD)NORTH CHICAGO, Ill., June 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today the acquisition of Celsius Therapeutics, Inc. ("Celsius"), a privately held biotechnology company pioneering new therapies for patients with inflammatory disease. Celsius' lead investigational asset is CEL383, a potential first-in-class anti-TREM1 antibod ...

Allē Members Enjoy the Aesthetic Treatments They Love Today, and Pay Over-Time with No Hard Credit Checks Participation Comes at No Cost* to Aesthetic Providers for Allergan Aesthetics Treatments and Products, Increasing Affordability of Treatments with Flexible Payment Options IRVINE, Calif., June 27, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today debuted Allē Payment Plans, powered by Cherry. By giving consumers the power to pay over-time for aesthetic treatments and pr ...

Tokyo, Japan and Cambridge, UK, 27 June 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration with AbbVie targeting neurological diseases, resulting in a payment of US$10 million to Nxera. Nxera and AbbVie entered into this multi-target collaboration in 2022 to leverage Nxera’s NxWave™ platform to discover, develop and commercialize new medicines targeting novel G protein-coupled receptor (GPCR) targets assoc ...

-  EPKINLY is now the first and only bispecific antibody approved in the U.S. to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL)-  Bispecific antibodies are designed to induce targeted cell killing by engaging the immune system-  FL is considered incurable with current standard of care therapies. Many people living with FL who have relapsed or are refractory to existing therapies have limited treatment options and reduced survival1NORTH CHICAGO, ...